← Leaderboards
Richard Carvajal
Sloan-Kettering Inst Can Research
$916,859
Attributed
$980,236
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $426.9K · FY2008–21$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$980,236 · 2
By mechanism
R21$980,236 · 2
Top collaborators
- Angela Jiyeon Yoon1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Pankaj Chaturvedi$1,198,588
- Milind Rajadhyaksha$15,078,152
- Ross L Levine$31,715,816
- Shakeel Modak$2,048,034
- Thomas Reiner$4,804,085
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyNeoplastic CellRecurrenceSurvival RateModalityClinical TrialsNeoplasm MetastasisOperative Surgical ProceduresToxic EffectTumorCancer ControlAftercareImmune TargetingG(M2) GangliosideAntigensAntibody FormationAdjuvant StudyImmunogenicityCellsDouble-Blind MethodCarrier ProteinsAntibodiesChemotherapyAdult
Grant awards (3)
Exploratory clinical trial of topical Imiquimod 5% cream as window-of-opportunity monotherapy for early-stage oral cancer$126,755
R21 · FY2021 · CA
Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV$426,600
R21 · FY2009 · CA · contact PI
Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV$426,881
R21 · FY2008 · CA · contact PI